Off-label prescribing in macular degeneration.
margaret@margaretmccartney.com
Margaret
M
McCartney
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000191:economics; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000191:economics; D000068258:Bevacizumab; D006801:Humans; D007880:Legislation, Drug; D008268:Macular Degeneration / Q000188:drug therapy* / Q000191:economics; D056687:Off-Label Use; D010818:Practice Patterns, Physicians'; D055553:Prescription Drugs / Q000008:administration & dosage / Q000191:economics; D000069579:Ranibizumab; D006113:United Kingdom
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D055553:Prescription Drugs; D000068258:Bevacizumab; D000069579:Ranibizumab